Biogen and Ionis report constructive topline scientific facts on investigational Alzheimer’s illness remedy at AAIC
CAMBRIDGE, Mass. and CARLSBAD, Calif., July 26, 2021 /PRNewswire/ — Biogen Inc. (Nasdaq: BIIB) and Ionis Prescription drugs, Inc. (Nasdaq: IONS) declared right now that topline facts from a Section 1b placebo-controlled, several ascending dose medical review showed that BIIB080/IONIS-MAPTRx satisfied its key objective of basic safety and tolerability in patients with gentle Alzheimer’s disorder. The review shown sturdy time and dose dependent decreasing of tau protein in cerebrospinal fluid (CSF) about the a few-thirty day period treatment interval and sustained reductions all through the six-month post-cure interval.
In clients obtaining BIIB080, there ended up dose-dependent decreases in